Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Dermata Therapeutics
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
June 13, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata to Present at the H.C. Wainwright Global Investment Conference
May 23, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 16, 2022
From
Dermata Therapeutics
Via
AccessWire
Exposures
Product Safety
Tickers
DRMA
DRMAW
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 25, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 21, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
March 28, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
March 24, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors
January 13, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata to Present at the H.C. Wainwright BioConnect Conference
January 05, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
November 19, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
November 17, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021
From
Dermata Therapeutics
Via
AccessWire
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
Tickers
DRMA
DRMAW
Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
November 12, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions
November 11, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
October 18, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 27, 2021
From
Dermata Therapeutics
Via
AccessWire
Topics
Initial Public Offering
Intellectual Property
Exposures
Intellectual Property
Product Safety
Securities Market
Tickers
DRMA
Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
September 21, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
September 01, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
August 17, 2021
From
Dermata Therapeutics
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Tickers
DRMA
DRMAW
Dermata Therapeutics, Inc. Announces Pricing of Upsized $18.0 Million Initial Public Offering
August 12, 2021
From
Dermata Therapeutics
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Tickers
DRMA
DRMAW
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit